K-CAB is in talks to extend refund-type PVA
By Lee, Tak-Sun | translator Kim, Jung-Ju
24.04.04 05:50:48
가나다라
0
The only item under the refund contract…After the initial contract in 2021, a three-years extension is under review
The company refunds the amount to the NHIS instead of reducing drug prices…The upper limit price is set to the same as the price listed in 2019
▲HK inno.N
HK inno.N is in talks with the National Health Insurance Service (NHIS) to extend the refund-type price-volume agreement (PVA) for K-CAB (tegoprazan), a drug developed in Korea for gastroesophageal reflux disease.K-CAB is the only drug under the refund-type price-volume agreement (PVA).
Since its release in 2019, K-CAB’s claim amount has been on the rise, so the contract extension is highly probable.
According to industry sources on April 3, HK inno.N is discussing with the NHIS to extend the refund-type price-volume agreement (PVA) for K-CAB.
In 2021, HK inno.N secured the the refund-type price-volume agreement (PVA) for K-CAB with the NHIS.
Lee, Tak-Sun(hooggasi2@dailypharm.com)
If you want to see the full article, please JOIN US (click)